MiR-539-5p Decreases amyloid β-protein production, hyperphosphorylation of Tau and Memory Impairment by Regulating PI3K/Akt/GSK-3β Pathways in APP/PS1 Double Transgenic Mice

被引:18
作者
Jiang, Yushu [1 ]
Zhang, Yuan [2 ]
Su, Li [3 ]
机构
[1] Henan Prov Peoples Hosp, Dept Neurol, Zhengzhou 450000, Henan, Peoples R China
[2] Shenzhen Univ, Shenzhen Peoples Hosp 2, Affiliated Hosp 1, Dept Neurosurg,Shenzhen Key Lab Neurosurg,Cent La, 3002 Sungang West Rd, Shenzhen 518035, Guangdong, Peoples R China
[3] Shenzhen Univ Gen Hosp, Dept Neurosurg, Shenzhen 518055, Guangdong, Peoples R China
关键词
MiR-539-5p; Amyloid beta-protein production; Tau; Hyperphosphorylation; PI3K/Akt/GSK-3 beta pathway; Alzheimer's disease; OXIDATIVE STRESS; NEUROFIBRILLARY TANGLES; ALZHEIMER-DISEASE; PATHOLOGY; APOPTOSIS; DEFICITS; PHOSPHORYLATION; ABNORMALITIES; BIOMARKER; MIRNA;
D O I
10.1007/s12640-020-00217-w
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The production of amyloid beta (A beta) and tau hyperphosphorylation have been identified as key processes in Alzheimer's disease (AD) pathogenesis. MiR-539-5p has been found to be abnormally expressed in brain tissue; however, the functional role of miR-539-5p in the pathogenesis of AD remains unclear. In our study, we found that the expression of miR-539-5p was significantly downregulated in humans and mice with AD and was negatively correlated with expression of APP, caveolin 1, and GSK-3 beta. Moreover, upregulation of miR-539-5p inhibited A beta accumulation, tau phosphorylation, oxidative stress, and apoptosis and improved memory ability in AD mice. Furthermore, by using bioinformatics tool and dual-luciferase reporter assay, APP, Caveolin 1, and GSK-3 beta were confirmed as direct targets of miR-539-5p. In addition, the PI3K/AKT/GSK-3 beta signaling pathway can be regulated by miR-539-5p. In conclusion, this study provided a novel insight into the pathologic mechanism of AD by identifying that miR-539-5p plays a neuroprotective role in AD.
引用
收藏
页码:524 / 535
页数:12
相关论文
共 47 条
  • [1] Bekris LM, 2015, NEURODEGENER DIS MAN, V5, P61, DOI [10.2217/NMT.14.52, 10.2217/nmt.14.52]
  • [2] Oxidative stress and altered mitochondrial protein expression in the absence of amyloid-β and tau pathology in iPSC-derived neurons from sporadic Alzheimer's disease patients
    Birnbaum, Julian H.
    Wanner, Debora
    Gietl, Anton F.
    Saake, Antje
    Kuendig, Thomas M.
    Hock, Christoph
    Nitsch, Roger M.
    Tackenberg, Christian
    [J]. STEM CELL RESEARCH, 2018, 27 : 121 - 130
  • [3] Alzheimer's Disease: Past, Present, and Future
    Bondi, Mark W.
    Edmonds, Emily C.
    Salmon, David P.
    [J]. JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY, 2017, 23 (9-10) : 818 - 831
  • [4] Neurofibrillary tangles and Alzheimer's disease
    Brion, JP
    [J]. EUROPEAN NEUROLOGY, 1998, 40 (03) : 130 - 140
  • [5] Non-canonical soluble amyloid-beta aggregates and plaque buffering: controversies and future directions for target discovery in Alzheimer's disease
    Brody, David L.
    Jiang, Hao
    Wildburger, Norelle
    Esparza, Thomas J.
    [J]. ALZHEIMERS RESEARCH & THERAPY, 2017, 9
  • [6] Oxidative stress and the amyloid beta peptide in Alzheimer's disease
    Cheignon, C.
    Tomas, M.
    Bonnefont-Rousselot, D.
    Faller, P.
    Hureau, C.
    Collin, F.
    [J]. REDOX BIOLOGY, 2018, 14 : 450 - 464
  • [7] Oxidative stress in Alzheimer's disease
    Chen, Zhichun
    Zhong, Chunjiu
    [J]. NEUROSCIENCE BULLETIN, 2014, 30 (02) : 271 - 281
  • [8] MicroRNA Profiling of CSF Reveals Potential Biomarkers to Detect Alzheimer's Disease
    Denk, Johannes
    Boelmans, Kai
    Siegismund, Christine
    Lassner, Dirk
    Arlt, Soenke
    Jahn, Holger
    [J]. PLOS ONE, 2015, 10 (05):
  • [9] The emerging role of microRNAs in Alzheimer's disease
    Femminella, Grazia D.
    Ferrara, Nicola
    Rengo, Giuseppe
    [J]. FRONTIERS IN PHYSIOLOGY, 2015, 6
  • [10] MiR-21 attenuates apoptosis-triggered by amyloid-β via modulating PDCD4/ PI3K/AKT/GSK-3β pathway in SH-SY5Y cells
    Feng, Mei-Guo
    Liu, Cui-Fang
    Chen, Li
    Feng, Wen-Bo
    Liu, Min
    Hai, Hua
    Lu, Jing-Min
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2018, 101 : 1003 - 1007